Jazz Pharmaceuticals (JAZZ) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

Allspring Global Investments Holdings LLC grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 1,326.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm o…

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.…

Boston Trust Walden Corp decreased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Th…

DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healt…

Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.…

Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pha…

Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript…

Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset pr…

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the y…

Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $3.88 per share versus the Zacks Consensus Estimate of a loss of $4.09. This compares to earnings of $8.13 per share a year ago.…

– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® revenues grew 12% YoY wi…

Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Na…

Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.…

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy d…

CWA Asset Management Group LLC lifted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 24.3% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exc…

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial mar…

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.…

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gro…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on …

Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potentia…

Jazz Pharmaceuticals (NASDAQ: JAZZ) executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Glob…

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment optio…

DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Heal…

HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ra…

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "n…

DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subjec…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

